Indiana PREGMED
印第安纳预科
基本信息
- 批准号:8600300
- 负责人:
- 金额:$ 88.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-02-01 至 2015-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAffectAlcohol consumptionAntidepressive AgentsBiochemicalBioethicsBioinformaticsBiological MarkersBlood VesselsCYP2C19 geneCYP2C9 geneCYP2D6 geneCYP3A4 geneCYP3A5 geneCaringChildClinicalClinical PharmacologyClinical ResearchDataData SetDisciplineDiscipline of obstetricsDiseaseDoseDrug KineticsEnvironmentEnzymesExposure toFetusFluoxetineGenesGenetic PolymorphismGoalsHTR2A geneIncidenceIndianaInfantInfant DevelopmentInstitutional Review BoardsKnowledgeLaboratoriesLeadLinkMeasuresMental DepressionMetabolismModelingMothersNeonatalNeonatologyOutcomePathway interactionsPatientsPharmaceutical PreparationsPharmacodynamicsPharmacogeneticsPharmacogenomicsPharmacologyPlasmaPopulationPostpartum DepressionPregnancyPregnancy OutcomePregnant WomenPrevalencePrincipal InvestigatorRecording of previous eventsResearchResearch DesignRiskSafetySamplingSelective Serotonin Reuptake InhibitorSerotoninSertralineTechnologyTestingTherapeuticTherapeutic StudiesTimeWomanWorkangiogenesisbasechild bearingclinical applicationclinical efficacycopingdepressive symptomsdrug metabolismexperiencehigh throughput technologyimprovedinnovationmaternal depressionneonatenovel strategiespharmacokinetic modelpre-clinicalserotonin transporterskillssuccesssuicidal
项目摘要
DESCRIPTION (provided by applicant): Within the world of therapeutics, immense changes have occurred over the last fifty years that have benefited millions. The fundamental purpose of this application for an Obstetric Pharmacology Research Unit is to bring skills and technologies that have been key to the therapeutic revolution to the study of therapeutics in pregnancy. Within a strong academic clinical obstetric environment, we plan to exploit expertise and experience in the discipline of clinical pharmacology, which has been key to the success of the broad therapeutic revolution. We plan to build on the success of our pilot Center, entitled PREGMED, focused on research designed to deliver more individualized care to pregnant women and their children. Our proposal involves the synthesis of strong clinical obstetrics with 5 key cores: 1) a drug analytical laboratory to measure small amounts of drugs in pregnant women and their children; 2) a pharmacogenomic core laboratory that will use new high throughput technologies to improve both the targeting of therapies and our understanding of their biochemical basis 3) A computation and bioinformatics core to model pharmacokinetic, pharmacodynamic changes in concert with pharmacogenomic and other biomarker data. 4) An angiogenesis biomarker core aimed at following vascular effects of drugs in these women. 5) a bioethics core that we believe is integral to both our clinical and our basic/preclinical work. To demonstrate the collective value of these cores, we propose linked basic and clinical studies designed to test the vascular effects of the SSRI class of antidepressants in pregnant women. We hypothesize that SSRI metabolism increases during pregnancy resulting in a decrease in patient exposure to the SSRI and subsequent worsening of depressive symptoms and depression scores during pregnancy. To test this hypothesis we propose two aims: i) To investigate the pharmacokinetic parameters and clinical efficacy of SSRI therapy as pregnancy progresses and ii) to examine how genetic polymorphisms of drug metabolizing enzymes and the serotonin pathway impact SSRI disposition and efficacy.
描述(由申请人提供):在治疗学的世界里,在过去的五十年里发生了巨大的变化,使数百万人受益。产科药理学研究单位的这一应用的基本目的是带来的技能和技术,一直是治疗革命的关键,在怀孕治疗的研究。在强大的学术临床产科环境中,我们计划利用临床药理学学科的专业知识和经验,这是广泛治疗革命成功的关键。我们计划在我们名为PREGMED的试点中心取得成功的基础上再接再厉,该中心专注于为孕妇及其子女提供更个性化护理的研究。我们的建议涉及强大的临床产科的合成与5个关键核心:1)药物分析实验室,以测量孕妇及其子女的少量药物; 2)药物基因组学核心实验室,将使用新的高通量技术来改善治疗的靶向和我们对其生化基础的理解3)计算和生物信息学核心来模拟药代动力学,药效学变化与药物基因组学和其他生物标志物数据一致。4)血管生成生物标志物核心旨在跟踪这些女性中药物的血管效应。5)我们认为生物伦理学核心是我们临床和基础/临床前工作不可或缺的。为了证明这些核心的集体价值,我们提出了相关的基础和临床研究,旨在测试SSRI类抗抑郁药对孕妇血管的影响。我们假设,SSRI代谢增加在怀孕期间导致患者暴露于SSRI和随后的抑郁症状和抑郁评分在怀孕期间恶化。为了验证这一假设,我们提出了两个目标:i)研究药物代谢酶和5-羟色胺途径的遗传多态性如何影响SSRI处置和疗效的药物代谢酶的药代动力学参数和SSRI治疗的临床疗效。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Patient attitudes toward genotyping in an urban women's health clinic.
城市妇女保健诊所患者对基因分型的态度。
- DOI:10.1097/aog.0b013e318187e77f
- 发表时间:2008
- 期刊:
- 影响因子:7.2
- 作者:Haas,DavidM;Renbarger,JamieL;Meslin,EricM;Drabiak,Katherine;Flockhart,David
- 通讯作者:Flockhart,David
Obstetric therapeutics-how pharmacogenetics may inform drug therapy for pregnant women in the future.
产科治疗——药物遗传学如何为未来孕妇的药物治疗提供信息。
- DOI:10.1097/ogx.0b013e3182a66180
- 发表时间:2013
- 期刊:
- 影响因子:6.2
- 作者:Haas,DavidM
- 通讯作者:Haas,DavidM
Antenatal corticosteroid therapy: current strategies and identifying mediators and markers for response.
产前皮质类固醇治疗:当前策略以及识别反应介质和标记物。
- DOI:10.1053/j.semperi.2014.08.018
- 发表时间:2014
- 期刊:
- 影响因子:3.4
- 作者:Falah,Nadia;Haas,DavidM
- 通讯作者:Haas,DavidM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID M. HAAS其他文献
DAVID M. HAAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID M. HAAS', 18)}}的其他基金
Machine learning approaches towards risk assessment and prediction of adverse pregnancy outcomes
用于风险评估和预测不良妊娠结局的机器学习方法
- 批准号:
10226370 - 财政年份:2020
- 资助金额:
$ 88.93万 - 项目类别:
Machine learning approaches towards risk assessment and prediction of adverse pregnancy outcomes
用于风险评估和预测不良妊娠结局的机器学习方法
- 批准号:
10453757 - 财政年份:2020
- 资助金额:
$ 88.93万 - 项目类别:
Machine learning approaches towards risk assessment and prediction of adverse pregnancy outcomes
用于风险评估和预测不良妊娠结局的机器学习方法
- 批准号:
10063323 - 财政年份:2020
- 资助金额:
$ 88.93万 - 项目类别:
Pharmacokinetics and modeling of betamethasone therapy in threatened preterm birth
先兆早产倍他米松治疗的药代动力学和模型
- 批准号:
9123871 - 财政年份:2016
- 资助金额:
$ 88.93万 - 项目类别:
Pharmacokinetics and modeling of betamethasone therapy in threatened preterm birth
先兆早产倍他米松治疗的药代动力学和模型
- 批准号:
10174278 - 财政年份:2016
- 资助金额:
$ 88.93万 - 项目类别:
Pharmacokinetics and modeling of betamethasone therapy in threatened preterm birth
先兆早产倍他米松治疗的药代动力学和模型
- 批准号:
9888973 - 财政年份:2016
- 资助金额:
$ 88.93万 - 项目类别:
Pregnancy as a Window to Future Cardiovascular Health
怀孕是未来心血管健康的窗口
- 批准号:
8576062 - 财政年份:2013
- 资助金额:
$ 88.93万 - 项目类别:
Dissecting the Genetic Etiology of Preterm Birth in Nulliparous Women
剖析未产妇早产的遗传病因
- 批准号:
8013029 - 财政年份:2010
- 资助金额:
$ 88.93万 - 项目类别:
Dissecting the Genetic Etiology of Preterm Birth in Nulliparous Women
剖析未产妇早产的遗传病因
- 批准号:
8204688 - 财政年份:2010
- 资助金额:
$ 88.93万 - 项目类别:
Dissecting the Genetic Etiology of Preterm Birth in Nulliparous Women
剖析未产妇早产的遗传病因
- 批准号:
8605888 - 财政年份:2010
- 资助金额:
$ 88.93万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 88.93万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 88.93万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 88.93万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 88.93万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 88.93万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 88.93万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 88.93万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 88.93万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 88.93万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 88.93万 - 项目类别:
Discovery Grants Program - Individual